Journal of Global Antimicrobial Resistance · 2021 · 76 citations · 14 references
MedicinePharmacokineticsPharmacologyAntimicrobial PharmacotherapyClinical PharmacologyPharmacodynamicsAntibiotic ResistanceCritical Care Therapeutic Drug MonitoringEmpiric Antimicrobial TherapyPharmacodynamics In Critical IllnessPharmacokinetics In Critical IllnessPharmacokinetics Of AntimicrobialsAcinetobacter Baumannii InfectionAcinetobacter Baumannii ResistanceCritical Care Antimicrobial TherapyDrug-resistant PathogensMicrobiological Outcome AssessmentPharmacodynamic Target AttainmentVentilator-associated PneumoniaVentilator-associated Pneumonia Treatment
The aim of this study was to explore the relationship between cefiderocol pharmacokinetic/pharmacodynamic (PK/PD) target attainment and microbiological outcome in critically ill patients affected by extensively drug-resistant Acinetobacter baumannii (XDR-AB) bloodstream infection (BSI) and/or ventilator-associated pneumonia (VAP). Patients who received compassionate use of cefiderocol to treat documented XDR-AB infections at the intensive care unit of the IRCCS Azienda Ospedaliero–Universitaria of Bologna and who underwent therapeutic drug monitoring (TDM) from 15 March 2021 to 30 April 2021 were retrospectively assessed. Cefiderocol trough concentration (Cmin) was determined at steady-state, and the free fraction (fCmin) was calculated according to a plasma protein binding of 58%. The fCmin/MIC ratio was selected as a pharmacodynamic parameter of cefiderocol efficacy and was defined as optimal if ≥4, quasi-optimal if between 1 and 4, and suboptimal if <1. The association between fCmin/MIC and microbiological outcome was assessed. A total of 13 patients treated with cefiderocol for the management of XDR-AB infections (6 BSI plus VAP, 5 VAP and 2 BSI) were retrieved. fCmin/MIC ratios were suboptimal in 3 cases (23%) and quasi-optimal or optimal in 5 cases each (38%). Microbiological failure occurred in seven cases (54%; six with VAP and one with VAP plus BSI). Microbiological failure occurred in 80% of patients with suboptimal fCmin/MIC compared with 29% of those achieving optimal or quasi-optimal fCmin/MIC ratio. Suboptimal attainment of PK/PD targets of cefiderocol may lead to microbiological failure of treatment with cefiderocol of critically ill patients affected by XDR-AB VAP.
14
Anna-Pelagia Magiorakos, Arjun Srinivasan, Roberta B. Carey et al. · Clinical Microbiology and Infection · 2011 · 14K citations
Matteo Bassetti, Roger Echols, Yuko Matsunaga et al. · The Lancet Infectious Diseases · 2020 · 792 citations
Ryan K. Shields, M. Hong Nguyen, Liang Chen et al. · Antimicrobial Agents and Chemotherapy · 2018 · 286 citations · Full text
Meredith Hackel, Masakatsu Tsuji, Yoshinori Yamano et al. · Antimicrobial Agents and Chemotherapy · 2017 · 234 citations · Full text
Krystyna M. Kazmierczak, Masakatsu Tsuji, Mark G. Wise et al. · International Journal of Antimicrobial Agents · 2018 · 191 citations · Full text